Literature DB >> 6580718

Graft-versus-host reaction in 3 adult leukaemia patients after transfusion of blood cell products.

J Nikoskelainen, K O Söderström, A Rajamäki, L Meurman, H Korvenranta, J L Kalliomäki, A Toivanen.   

Abstract

We describe 3 cases of acute graft-versus-host (GVH) disease in patients with acute myeloid leukaemia following transfusions taken from non-HLA-identical healthy donors. The leucocyte transfusions were given because of severe bone marrow aplasia and granulocytopenia following leukaemia induction treatment. The first patient had an acute GVH reaction with an erythrodermia-like skin reaction all over and associated with severe abdominal cramping, enlarged liver and pathological liver function tests. The second patient had a relatively mild skin reaction and enlarged liver. Both died of severe pulmonary infection. The third patient also had a mild skin reaction and enlarged liver. He died of pulmonary embolism. The diagnosis of GVH of the latter 2 cases was made on skin biopsy. The autopsy samples revealed in all cases a heavy lymphocytic infiltration of the kidneys and liver portal area. Until more precise guidelines can be established, irradiation of blood cell products given to patients with neutropenia due to leukaemia induction treatment should be considered.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6580718     DOI: 10.1111/j.1600-0609.1983.tb01533.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  2 in total

1.  Luminol-enhanced chemiluminescence of peripheral blood leukocytes as an early indicator of graft take after allogeneic bone marrow transplantation in patients with acute myelogenous leukaemia.

Authors:  A Rajamäki; E M Lilius; J Nikoskelainen; J Proskin; T T Salmi; A Toivanen
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

Review 2.  Granulocyte transfusions in the management of invasive fungal infections.

Authors:  Kamille A West; Juan Gea-Banacloche; David Stroncek; Sameer S Kadri
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.